- Home
- KAVL vs POAI Comparison
KAVL vs POAI Comparison
Compare KAVL & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- POAI
- Stock Information
- Founded
- KAVL 1998
- POAI 2002
- Country
- KAVL United States
- POAI United States
- Employees
- KAVL N/A
- POAI N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- POAI Industrial Specialties
- Sector
- KAVL Health Care
- POAI Health Care
- Exchange
- KAVL Nasdaq
- POAI Nasdaq
- Market Cap
- KAVL 8.9M
- POAI 8.5M
- IPO Year
- KAVL N/A
- POAI N/A
- Fundamental
- Price
- KAVL $1.18
- POAI $1.48
- Analyst Decision
- KAVL
- POAI Hold
- Analyst Count
- KAVL 0
- POAI 1
- Target Price
- KAVL N/A
- POAI N/A
- AVG Volume (30 Days)
- KAVL 1.1M
- POAI 3.7M
- Earning Date
- KAVL 02-13-2025
- POAI 11-12-2024
- Dividend Yield
- KAVL N/A
- POAI N/A
- EPS Growth
- KAVL N/A
- POAI N/A
- EPS
- KAVL N/A
- POAI N/A
- Revenue
- KAVL $10,108,906.00
- POAI $1,484,223.00
- Revenue This Year
- KAVL $652.90
- POAI N/A
- Revenue Next Year
- KAVL N/A
- POAI $569.48
- P/E Ratio
- KAVL N/A
- POAI N/A
- Revenue Growth
- KAVL N/A
- POAI N/A
- 52 Week Low
- KAVL $0.58
- POAI $0.55
- 52 Week High
- KAVL $9.69
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- KAVL 60.50
- POAI 61.56
- Support Level
- KAVL $0.95
- POAI $1.16
- Resistance Level
- KAVL $1.22
- POAI $1.42
- Average True Range (ATR)
- KAVL 0.20
- POAI 0.43
- MACD
- KAVL 0.02
- POAI 0.00
- Stochastic Oscillator
- KAVL 51.76
- POAI 31.00
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.